This duality demands precision in targeted therapy, aiming to preserve NRF2′s cytoprotective function in healthy tissues while avoiding the chronic activation that promotes tumor survival, invasion, and treatment resistance. The gene discussed is NFE2L2; the disease is neoplasm.